リラグルチドとセマグルチドの世界市場

リラグルチドとセマグルチドの世界市場は2030年までに298億米ドルに達する見込み

2024年に171億米ドルと推定されるリラグルチドとセマグルチドの世界市場は、2024～2030年の分析期間においてCAGR 9.7%で成長し、2030年には298億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである錠剤は、CAGR 8.0%を記録し、分析期間終了時には174億米ドルに達すると予測されます。液剤セグメントの成長率は、分析期間中CAGR 12.5％と推定されます。

米国市場は46億米ドルと推定、中国はCAGR13.0％で成長予測

米国のリラグルチドとセマグルチド市場は、2024年には46億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに60億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.1%と8.4%と予測されています。欧州では、ドイツがCAGR 7.6%で成長すると予測されています。

世界のリラグルチドとセマグルチド市場- 主要動向と促進要因のまとめ

リラグルチドとセマグルチドが糖尿病・肥満治療に変革をもたらす理由とは？

リラグルチドとセマグルチド、2つの著名なグルカゴン様ペプチド-1（GLP-1）受容体作動薬は、2型糖尿病と肥満の管理におけるゲームチェンジャーとして登場しました。これらの薬剤は、インスリン分泌を促進し、食欲を抑制し、胃排出を遅らせることにより、血糖コントロールの改善と大幅な体重減少をもたらします。世界的に糖尿病と肥満の有病率が増加していることから、従来の抗糖尿病薬と比較して優れた効果を発揮することから、これらの治療薬に対する需要が急増しています。インスリン治療とは異なり、リラグルチドとセマグルチドのようなGLP-1受容体作動薬は、体重管理を促進しながら低血糖のリスクを低減するため、患者にとってもヘルスケアプロバイダーにとっても魅力的な選択肢となります。心血管系への有用性を裏付ける臨床エビデンスの増加により、規制当局や医療機関はその使用を推奨し続けており、採用率はさらに高まっています。製薬企業がさらなる研究と技術革新に投資する中、代謝性疾患におけるGLP-1アナログの役割は拡大し、糖尿病および体重管理治療における市場での地位は確固たるものになると予想されます。

リラグルチドとセマグルチド製剤における最新のイノベーションとは？

技術の進歩と研究開発により、リラグルチドとセマグルチドの製剤は顕著な改善を遂げ、その有効性、患者のコンプライアンス、投与の利便性が向上しています。最も重要なブレークスルーの一つは、経口セマグルチドの導入であり、皮下注射の必要性をなくし、患者のアドヒアランスの大きな障壁に対処しています。この技術革新により、特に注射薬よりも経口薬を好む患者の間で、利用しやすさが拡大しました。さらに、徐放性製剤や高用量製剤も、減量効果を最適化し血糖コントロールを改善するために開発されています。GLP-1受容体作動薬とナトリウムグルコース共輸送体-2（SGLT2）阻害薬など他の代謝性薬剤との併用も、糖尿病管理における相乗効果を生み出すために検討されています。製薬会社はまた、不快感を最小限に抑えながら投与を容易にするプレフィルドペンや自動注射器にも投資しています。非アルコール性脂肪性肝疾患（NAFLD）や心血管疾患への応用など、これらの薬剤の広範な治療可能性を調査する臨床試験が進行中であり、リラグルチドとセマグルチドにおける製剤の進歩は、代謝性疾患治療の未来を形成し続けています。

市場の需要はGLP-1治療薬の成長にどのような影響を与えているか？

リラグルチドとセマグルチドのようなGLP-1受容体作動薬に対する世界の需要は、2型糖尿病と肥満の負担の増加により急増しています。ヘルスケアプロバイダーは、代謝性疾患に対する効果的かつ長期的な解決策を優先しており、GLP-1療法は広く受け入れられています。また、体重減少や心血管への効果を促進する非インスリン療法への嗜好が高まっていることも、市場拡大にさらに寄与しています。さらに、テレヘルスやデジタルヘルスプラットフォームの拡大により、オンライン診察や電子処方箋が治療の開始とアドヒアランスを促進するため、これらの治療薬への患者アクセスが向上しています。また、健康意識の高まりや患者の代謝異常に対する積極的な管理も、GLP-1治療薬に対する需要を後押ししています。さらに、製薬企業は糖尿病患者だけでなく、肥満管理分野もターゲットとしてマーケティング活動を拡大しており、これは大きな成長機会となっています。保険償還政策がより有利になり、ジェネリック医薬品が市場に参入するにつれて、リラグルチドとセマグルチドへのアクセシビリティは向上し、代謝異常の基礎治療としての役割が強化されると予想されます。

リラグルチドとセマグルチド市場を促進する主な成長要因は？

リラグルチドとセマグルチド市場の成長は、肥満と糖尿病の世界の有病率の上昇、治療ガイドラインにおけるGLP-1受容体作動薬の採用の増加、継続的な医薬品の進歩など、いくつかの重要な要因によってもたらされます。個別化医療や患者中心の治療が重視されるようになったことで、血糖コントロールと体重管理の両方のメリットをもたらす治療薬に対する需要が高まっています。さらに、GLP-1療法の心血管系への有益性に関する研究が拡大したことで、これらの薬剤はリスクの高い糖尿病患者にとって不可欠な治療薬としてさらに位置付けられています。また、高血圧や脂質異常症など肥満に関連する合併症の急増により、医療従事者はGLP-1受容体作動薬を多剤併用療法に組み入れるなど、総合的な治療アプローチを採用するようになっています。もう一つの重要な促進要因は、新規GLP-1ベースの治療薬の強力なパイプラインであり、製薬会社は有効性の改善、副作用の軽減、患者のアドヒアランスの向上を実現する次世代製剤の開発に積極的に取り組んでいます。生活習慣の改善や予防ヘルスケアへの取り組みの動向は、これらの薬剤の早期採用をさらに後押しし、長期的な代謝疾患管理における役割を確固たるものにしています。認知度の向上、利用しやすさの改善、継続的な医療の進歩により、市場情勢は持続的な成長を遂げ、世界の糖尿病・肥満治療の状況を一変させるものと思われます。

セグメント

製品タイプ（錠剤、液剤）、投与経路（非経口投与、経口投与）、流通チャネル（病院薬局、小売薬局）、用途（2型糖尿病、肥満症）

調査対象企業の例

• AbbVie Inc.
• AstraZeneca
• Bachem Holding AG
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb（BMS）
• Cadila Pharmaceuticals
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc（GSK）
• Johnson & Johnson
• Kyowa Kirin Co., Ltd.
• Merck & Co., Inc.
• Novartis International AG
• Novo Nordisk A/S
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Liraglutide and Semaglutide Market to Reach US$29.8 Billion by 2030

The global market for Liraglutide and Semaglutide estimated at US$17.1 Billion in the year 2024, is expected to reach US$29.8 Billion by 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Pills, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$17.4 Billion by the end of the analysis period. Growth in the Liquid segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 13.0% CAGR

The Liraglutide and Semaglutide market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global Liraglutide and Semaglutide Market - Key Trends & Drivers Summarized

Why Are Liraglutide and Semaglutide Transforming Diabetes and Obesity Treatment?

Liraglutide and semaglutide, two prominent glucagon-like peptide-1 (GLP-1) receptor agonists, have emerged as game-changers in the management of type 2 diabetes and obesity. These medications work by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying, leading to improved blood sugar control and significant weight loss. The increasing prevalence of diabetes and obesity worldwide has driven a surge in demand for these therapeutics, as they offer superior efficacy compared to traditional antidiabetic medications. Unlike insulin therapy, GLP-1 receptor agonists like liraglutide and semaglutide provide a lower risk of hypoglycemia while promoting weight management, making them an attractive choice for patients and healthcare providers alike. With growing clinical evidence supporting their cardiovascular benefits, regulatory agencies and medical organizations continue to endorse their use, further boosting adoption rates. As pharmaceutical companies invest in further research and innovation, the role of these GLP-1 analogs in metabolic disorders is expected to expand, solidifying their market position in diabetes and weight management therapies.

What Are the Latest Innovations in Liraglutide and Semaglutide Formulations?

Technological advancements and research developments have led to notable improvements in the formulations of liraglutide and semaglutide, enhancing their effectiveness, patient compliance, and administration convenience. One of the most significant breakthroughs is the introduction of oral semaglutide, which eliminates the need for subcutaneous injections, addressing a major barrier to patient adherence. This innovation has expanded accessibility, particularly among individuals who prefer oral medications over injectables. Additionally, sustained-release formulations and higher-dose versions have been developed to optimize weight loss outcomes and improve glycemic control. The combination of GLP-1 receptor agonists with other metabolic drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, is also being explored to create synergistic effects in diabetes management. Pharmaceutical companies are also investing in pre-filled pens and auto-injectors that enhance ease of administration while minimizing discomfort. With ongoing clinical trials investigating the broader therapeutic potential of these drugs, including applications in non-alcoholic fatty liver disease (NAFLD) and cardiovascular health, the formulation advancements in liraglutide and semaglutide continue to shape the future of metabolic disease treatment.

How Is Market Demand Influencing the Growth of GLP-1 Therapies?

The global demand for GLP-1 receptor agonists such as liraglutide and semaglutide has surged due to the rising burden of type 2 diabetes and obesity, both of which have reached epidemic proportions. With healthcare providers prioritizing effective and long-term solutions for metabolic diseases, GLP-1 therapies have gained widespread acceptance. The growing preference for non-insulin therapies that promote weight loss and cardiovascular benefits has further contributed to their market expansion. Additionally, the expansion of telehealth and digital health platforms has improved patient access to these medications, as online consultations and e-prescriptions facilitate treatment initiation and adherence. The rising health awareness and proactive management of metabolic disorders among patients have also driven the demand for GLP-1 therapies, as individuals seek treatments that align with holistic wellness goals. Furthermore, pharmaceutical companies are expanding their marketing efforts, targeting not only diabetes patients but also the obesity management sector, which represents a significant growth opportunity. As reimbursement policies become more favorable and generic alternatives enter the market, accessibility to liraglutide and semaglutide is expected to increase, reinforcing their role as cornerstone treatments for metabolic disorders.

What Are the Primary Growth Drivers Fueling the Liraglutide and Semaglutide Market?

The growth in the liraglutide and semaglutide market is driven by several key factors, including the rising global prevalence of obesity and diabetes, increased adoption of GLP-1 receptor agonists in treatment guidelines, and continuous pharmaceutical advancements. The increasing emphasis on personalized medicine and patient-centered care has bolstered demand for therapies that offer both glycemic control and weight management benefits. Additionally, expanding research into the cardiovascular benefits of GLP-1 therapies has further positioned these medications as essential treatments for high-risk diabetic patients. The surge in obesity-related comorbidities, such as hypertension and dyslipidemia, has also prompted healthcare providers to adopt a holistic treatment approach, integrating GLP-1 receptor agonists into multimodal therapy plans. Another crucial growth driver is the strong pipeline of novel GLP-1-based treatments, with pharmaceutical companies actively developing next-generation formulations that improve efficacy, reduce side effects, and enhance patient adherence. The growing trend of lifestyle modifications and preventive healthcare initiatives has further encouraged early adoption of these medications, solidifying their role in long-term metabolic disease management. With increasing awareness, improved accessibility, and continuous medical advancements, the liraglutide and semaglutide market is set to witness sustained growth, transforming the landscape of diabetes and obesity treatment worldwide.

SCOPE OF STUDY:

The report analyzes the Liraglutide and Semaglutide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Pills, Liquid); Administration Route (Parenteral Administration, Oral Administration); Distribution Channel (Hospital Pharmacies, Retail Pharmacies); Application (Type 2 Diabetes Mellitus, Obesity)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• AstraZeneca
• Bachem Holding AG
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb (BMS)
• Cadila Pharmaceuticals
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Kyowa Kirin Co., Ltd.
• Merck & Co., Inc.
• Novartis International AG
• Novo Nordisk A/S
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Liraglutide and Semaglutide - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Type 2 Diabetes and Obesity Worldwide Drives Demand for Liraglutide and Semaglutide Therapies
  • Expansion of GLP-1 Receptor Agonist Usage Throws the Spotlight on Cardiometabolic Health Benefits
  • OEM Focus on Weekly and Daily Dosing Regimens Strengthens Adherence Across Patient Populations
  • Growth in Off-Label Use for Weight Loss and Metabolic Syndrome Spurs Market Expansion Beyond Diabetes
  • Regulatory Approvals for Cardiovascular Risk Reduction in High-Risk Patients Enhance Therapeutic Utility
  • OEM Innovation in Oral Semaglutide Delivery Platforms Expands Options for Injection-Averse Patients
  • Increased Access Through National Formularies and Reimbursement Programs Accelerates Prescription Uptake
  • Surge in Patient Preference for Once-Weekly GLP-1 Agonists Fuels Market Shift Toward Long-Acting Agents
  • Expansion of Obesity Treatment Guidelines by Global Health Authorities Strengthens Clinical Case for GLP-1 Agonists
  • OEM Collaboration With Digital Health Platforms and Patient Engagement Tools Enhances Treatment Adherence
  • Rising Demand for Personalized Dosing and Titration Algorithms Supports Patient-Centric Formulation Development
  • Growth in Telemedicine and Virtual Clinics Promotes Access to GLP-1 Therapy for Underserved Populations
  • OEM Emphasis on Cardiovascular and Renal Outcome Trials Builds Evidence for Expanded Label Indications
  • Increased Focus on Pre-Diabetes and Early Intervention Strategies Strengthens Demand for Preventive Use
  • Surge in Global Obesity-Related Health Costs Supports Government-Backed Adoption of Weight-Reduction Agents
  • OEM Partnerships With Retail Pharmacies and Care Management Networks Enhance Dispensing and Compliance
  • Regulatory Pipeline for Pediatric and Adolescents With Obesity Creates Long-Term Market Opportunities
  • Rising Investment in Fixed-Dose Combinations and Co-Formulations With Insulin or SGLT2 Inhibitors Enhances Value
  • Emergence of Biosimilars and Price Competition Expected to Reshape Market Access and Affordability Dynamics
  • Focus on Real-World Evidence and Health Economic Outcomes Strengthens Payer and Provider Confidence
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Liraglutide and Semaglutide Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Liraglutide and Semaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Liraglutide and Semaglutide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pills by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pills by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Pills by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Liquid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Type 2 Diabetes Mellitus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Type 2 Diabetes Mellitus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• JAPAN
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• CHINA
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• EUROPE
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Liraglutide and Semaglutide by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Liraglutide and Semaglutide by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• FRANCE
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• GERMANY
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 128: UK Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 155: Russia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Russia Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Russia 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 158: Russia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Russia Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Russia 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Europe Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Europe 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Europe Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Europe 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Europe Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Europe 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 177: Asia-Pacific Historic Review for Liraglutide and Semaglutide by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Asia-Pacific Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Asia-Pacific Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 191: Australia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Australia Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Australia 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 194: Australia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Australia Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Australia 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 197: Australia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Australia Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Australia 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• INDIA
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 203: India Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: India Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: India 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 206: India Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: India Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: India 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 209: India Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: India Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: India 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 212: India Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 215: South Korea Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: South Korea Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: South Korea 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 218: South Korea Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: South Korea Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: South Korea 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 221: South Korea Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: South Korea Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: South Korea 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 227: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Asia-Pacific Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Asia-Pacific Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Asia-Pacific Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 239: Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Latin America Historic Review for Liraglutide and Semaglutide by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Latin America 15-Year Perspective for Liraglutide and Semaglutide by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 242: Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Latin America Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Latin America 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 245: Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Latin America Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Latin America 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 254: Argentina Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Argentina Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Argentina 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 257: Argentina Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Argentina Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Argentina 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 260: Argentina Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Argentina Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Argentina 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 266: Brazil Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Brazil Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Brazil 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 269: Brazil Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Brazil Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Brazil 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 272: Brazil Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Brazil Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Brazil 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 278: Mexico Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Mexico Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Mexico 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 281: Mexico Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Mexico Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Mexico 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 284: Mexico Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Mexico Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Mexico 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 290: Rest of Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Latin America Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Latin America 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Latin America Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Latin America 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Latin America Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Latin America 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 302: Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 303: Middle East Historic Review for Liraglutide and Semaglutide by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Middle East 15-Year Perspective for Liraglutide and Semaglutide by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 305: Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Middle East Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Middle East 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 308: Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Middle East Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Middle East 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 317: Iran Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Iran Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Iran 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 320: Iran Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Iran Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Iran 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 323: Iran Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Iran Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Iran 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 329: Israel Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Israel Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Israel 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 332: Israel Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Israel Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Israel 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 335: Israel Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Israel Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Israel 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 341: Saudi Arabia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Saudi Arabia Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Saudi Arabia 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 344: Saudi Arabia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Saudi Arabia Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Saudi Arabia 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Saudi Arabia Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Saudi Arabia 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 353: UAE Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: UAE Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: UAE 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 356: UAE Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: UAE Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: UAE 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 359: UAE Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: UAE Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: UAE 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 365: Rest of Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Rest of Middle East Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Rest of Middle East 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 368: Rest of Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Rest of Middle East Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Rest of Middle East 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Rest of Middle East Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Rest of Middle East 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030
• AFRICA
  • Liraglutide and Semaglutide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 377: Africa Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Product Type - Pills and Liquid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Africa Historic Review for Liraglutide and Semaglutide by Product Type - Pills and Liquid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Africa 15-Year Perspective for Liraglutide and Semaglutide by Product Type - Percentage Breakdown of Value Sales for Pills and Liquid for the Years 2015, 2025 & 2030
  • TABLE 380: Africa Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Africa Historic Review for Liraglutide and Semaglutide by Administration Route - Parenteral Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Africa 15-Year Perspective for Liraglutide and Semaglutide by Administration Route - Percentage Breakdown of Value Sales for Parenteral Administration and Oral Administration for the Years 2015, 2025 & 2030
  • TABLE 383: Africa Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Africa Historic Review for Liraglutide and Semaglutide by Distribution Channel - Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Africa 15-Year Perspective for Liraglutide and Semaglutide by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Liraglutide and Semaglutide by Application - Type 2 Diabetes Mellitus and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Liraglutide and Semaglutide by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus and Obesity for the Years 2015, 2025 & 2030

IV. COMPETITION